The nation of Zimbabwe has rejected a substantial American health deal worth $367m (272 million pounds) spanning five years due to Washington's request for confidential biological samples.
This rejection became public following a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government spokesperson has since explained that the United States was requesting biological samples for scientific study and commercial purposes but was not willing to share the resulting advantages from any future vaccines.
"We must now begin the challenging and unfortunate task of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for continued negotiations to reach a deal agreeable to both sides so the country's critical HIV treatment initiative can continue.
Wider Context
This development follows a similar case in neighbouring Kenya, where a high court blocked a similar deal with the US after concerns were filed about the security of citizens' health data.
Since resuming office last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral deals to enhance transparency and responsibility.
As per reports, 16 nations in Africa have so far signed these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Declined Agreement
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation could have provided immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, without any equivalent assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our nation would provide the raw materials for medical research with no certainty that the resulting innovations would be available to our people should a future health crisis emerge."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral deals were disrupting systems already set up through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with potential global health emergencies.
"This framework is designed to ensure that when a nation provides its information, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage ongoing discussions with our American counterparts on how future collaboration might be designed in a way that honours the independence and interests of both nations."
Health Experts Reaction
A leading public health body said it acknowledged the government's concerns, but suggested that negotiations should continue considering much of the nation's HIV programmes were funded by foreign aid.
"In cases where specific concerns exist, including those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," it said.
The halted deal emphasises the ongoing challenges between receiving much-needed international aid and safeguarding national sovereignty in an ever more data-driven world.